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Mycobacterium tuberculosis progresses through two
phases of latent infection in humans
Roberto Colangeli1,8, Aditi Gupta1,8, Solange Alves Vinhas2,8, Uma Deepthi Chippada Venkata1, Soyeon Kim3,
Courtney Grady1, Edward C. Jones-López 4, Patricia Soteropoulos5,6, Moisés Palaci2,
Patrícia Marques-Rodrigues2, Padmini Salgame1, Jerrold J. Ellner1, Reynaldo Dietze2,7 & David Alland 1✉
Little is known about the physiology of latentMycobacterium tuberculosis infection. We studied
the mutational rates of 24 index tuberculosis (TB) cases and their latently infected household
contacts who developed active TB up to 5.25 years later, as an indication of bacterial phy-
siological state and possible generation times during latent TB infection in humans. Here we
report that the rate of new mutations in the M. tuberculosis genome decline dramatically after
two years of latent infection (two-sided p < 0.001, assuming an 18 h generation time equal to
log phase M. tuberculosis, with latency period modeled as a continuous variable). Alter-
natively, assuming a fixed mutation rate, the generation time increases over the latency
duration. Mutations indicative of oxidative stress do not increase with increasing latency
duration suggesting a lack of host or bacterial derived mutational stress. These results
suggest that M. tuberculosis enters a quiescent state during latency, decreasing the risk for
mutational drug resistance and increasing generation time, but potentially increasing bac-
terial tolerance to drugs that target actively growing bacteria.
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Human infection with Mycobacterium tuberculosis pro-duces an active form of disease known as tuberculosis(TB) or an asymptomatic form known as latent tuber-
culosis infection (LTBI)1. In LTBI, M. tuberculosis has been
assumed to exist in a quiescent state, constrained by host immune
responses within granulomas or other protected sites2. LTBI
carries an ~5–15% risk of progressing to active TB within the first
two years after infection. This is followed by an additional ~5%
risk of developing active TB over the remaining lifetime of the
infected host, usually due to waning immunity from disease or
aging2–4, although the true incidence of late TB recurrence during
latency has recently been questioned5. Almost two billion of the
world’s population shows evidence of past M. tuberculosis
infection, and if latently infected, may represent a major reservoir
for new disease and a source of new M. tuberculosis
transmission6,7. Recent studies have challenged a binary model of
M. tuberculosis infection, which subdivides disease states into
latent infection and active disease8–11. Instead, LTBI has been
proposed to represent a spectrum ranging from immunological
reactivity to a past cured infection, to sustained quiescent infec-
tion, to early low-level TB disease5,8,12,13. This model not only
redefines latency, but also suggests that different types of pre-
ventive treatment might be more appropriate for different types
of LTBI, assuming that the states of LTBI could be better iden-
tified in individual patients10.
Understanding the physiological state of M. tuberculosis during
latency is important for understanding the true impact of past M.
tuberculosis infections on future TB, for identifying patients at
high-risk of reactivation and for developing more efficient LTBI
treatments. A critical part of these studies is a determination of
whether M. tuberculosis is physiologically active, undergoing
replication and mutagenesis during LTBI, or whether it exists in a
quiescent state. In living organisms, genetic changes often occur
at a steady rate per generation. For example, species with shorter
generation times (i.e. the time required for bacteria to double in
number, a measure of replication rate) tend to have higher rates
of molecular evolution14. These observations have suggested that
the number of mutations that occur over a defined period can be
used as a “molecular clock” that provides an estimate of gen-
eration time (or replication rate) within a bacterial species15,16.
Several studies have utilized molecular clocks to study the
molecular evolution of M. tuberculosis17–19. Using cynomolgus
macaques as a model for studying LTBI, Ford et al. showed that
the mutation rates (i.e. the number of mutations that occur per
generation time) occurring over a broad range of potential gen-
eration times in M. tuberculosis isolated from latent lesions and
reactivated infections (cultured on average 41.7 and 68.1 weeks
after infection, respectively) were comparable to those of M.
tuberculosis isolated from patients with active pulmonary dis-
ease20. This work suggested that latent M. tuberculosis has gen-
eration times that are similar to that observed in active TB (or else
mutation rates are much higher during latency). In contrast,
Colangeli et al. performed a similar analysis comparing M.
tuberculosis mutation rates in two TB patients with little to no
latency period before symptomatic disease versus two patients
with reactivated TB after two decades long latency period iden-
tified during a TB outbreak investigation in New Zealand. These
results suggested that generation times are substantially longer
during latency compared to active disease (or else mutation rates
are far lower during latency)21. These conflicting studies illustrate
how poorly the mutation rate, generation time, and the accom-
panying physiological and metabolic status of M. tuberculosis are
understood during LTBI.
Here, we investigate the mutation rate and potential generation
time of M. tuberculosis during LTBI by analyzing whole-genome
M. tuberculosis sequences from 24 paired index TB cases and
their latently infected household contacts (HHCs) who were
diagnosed with active TB 0–63 months after exposure. This first
comprehensive study of M. tuberculosis mutation rates and gen-
eration times during latent infection shows that bacterial muta-
tion rates appear to decline 1–2 years after transmission,
coinciding with the clinical risk of developing active TB. These
findings enable us to make predictions about treatment efficacy
and the risk for developing bacterial drug resistance during LTBI
treatment.
Results
Participant enrollment. We measured the number of single
nucleotide polymorphism (SNP) differences that existed between
M. tuberculosis cultured from TB patients (index cases, IC) and
the same M. tuberculosis strain cultured from secondary TB cases
discovered among their HHCs. These results were then used to
estimate the range of possible mutation rates and generation
times of M. tuberculosis during LTBI. In a previously described
HHC study performed in Vitória, Brazil between February 2008
and October 201322, we had identified 160 households that fit the
case definition of containing a highly infectious case of acid-fast
bacilli (AFB) smear-positive pulmonary TB, had at least three
HHCs, and did not fulfill any exclusion criteria. Between the
beginning of the HHC study in 2008 and the end of the study in
2015, 72 HHCs associated with 62 of these ICs were found to
have developed active TB (Fig. 1). One IC–HHC pair was
excluded due to lack of consent for TB genome analysis. A search
though the local laboratory database located cultures from 43 of
the remaining HHCs with TB, each linked to its known IC,
resulting in 43 “TB pairs”. To assess the genetic relatedness of
each M. tuberculosis isolate within a TB pair, restriction fragment
polymorphism (RFLP) analysis was performed on all isolates
(Supplementary Fig. 1). Thirteen (30%) of the M. tuberculosis
isolates within a TB pair differed by more than one band and
were excluded from further analysis, due to an increased prob-
ability that the secondary case in the household had disease
caused by a different M. tuberculosis strain than the one that
infected the IC. In addition, the RFLP patterns of M. tuberculosis
samples from two TB pairs matched that of M. tuberculosis iso-
lates commonly circulating in the Vitória community (here,
isolates that shared RFLP with >10 other isolates are considered
as commonly circulating strains)23. These TB pairs were also
excluded, as transmission between the IC and secondary HHC
case could not be differentiated from the community circulating
strain. Two TB pairs were excluded because the cultures of the
secondary case could not be re-grown. The genomic DNA
extracted from a confluent plate of each participant’s sputum
culture (too many colonies to count) of the remaining 26 TB pairs
was purified and whole genome sequencing (WGS) was per-
formed. One TB pair was excluded after sequencing because of
poor genomic coverage and read depth. The average genomic
coverage was 97.3% across all other isolates with an average read
depth of 498× (Supplementary Table 1). One final TB pair was
excluded after sequencing because phylogenetic analysis indicated
that the two isolates did not share a most recent common
ancestor (Supplementary Fig. 2). This analysis strongly suggested
that the two individuals in this pair were infected with unrelated
M. tuberculosis isolates, which was a pre-specified exclusion cri-
terion. These exclusions left 24 TB pairs for subsequent analysis.
Comparing these TB pair strains to a DNA fingerprinting study
of 1357 M. tuberculosis isolates detected in the Vitória commu-
nity between 1999 and 201524, revealed that 14 of the TB pairs
included in our analysis had RFLP patterns that were unique to
the TB pair and did not share a RFLP pattern with any other
isolate studied in the community. The remaining 10 TB pairs
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shared RFLP patterns with 3–7 other isolates in the community
(medium-size cluster24). We also did not find evidence of mixed
infection in any of the 24 TB pairs (Supplementary Fig. 3). All
clinical isolates in this study were found to belong to M. tuber-
culosis lineage 4.
Clinical characteristics. Clinical characteristics of seven second-
ary cases were not available because these HHCs had not been
selected for detailed evaluation in the parent study. The clinical
characteristics of HHC cases for which clinical information was
available are shown in Table 1. The HHC were mostly young
adults with relatively low prevalence of co-morbidities, and
moderate smoking and alcohol use. Most HHCs had evidence of
BCG vaccination by the presence of a characteristic scar. None of
the clinical characteristics of HHCs with early (0–2 years) versus
late (>2 years) reactivation of TB disease were statistically
distinguishable.
The number of SNPs between IC and HHC isolates does not
increase with duration of latency. A phylogenetic tree was
constructed for the 48 genomes in the 24 validated TB pairs. This
analysis demonstrated that the M. tuberculosis isolates in the IC
and the HHC within each TB pair differed from each other by an
average of 2.25 SNPs (Supplementary Table 2), whereas the ICs
and HHCs from unrelated TB pairs differed on average by 559.6
SNPs (Supplementary Fig. 4), supporting the epidemiological
connection between each TB pair (Fig. 2). Next, we examined the
number of SNPs that developed between each IC and the paired
secondary TB case as a function of the time that separated the TB
diagnosis in the pair. Figure 3a shows a scatterplot of the months
between diagnoses and number of SNPs of the TB pairs with a
loess smoothed curve. A Poisson regression model was fit to the
difference in number of SNPs between IC–HHC pairs using
months between the diagnoses as a linear term. Because of the
small sample size and an estimated variance substantially higher
than the mean, we used robust standard errors for statistical
inference. Here, we assumed that the HHC was exposed to
infection when the IC was diagnosed with active tuberculosis
disease, and thus, the number of SNPs between the clinical iso-
lates from IC and HHC reflected the approximate number of
bacterial mutations that occurred between the time of IC diag-
nosis and the HHC diagnosis. Our results show that the number
of SNPs that differed between the M. tuberculosis genomic DNA
of the ICs and their matched HHCs did not increase with the
duration of the latency period (Fig. 3a, two-sided p= 0.90). This
was unchanged with the exclusion of the outlier pair with SNP
Eligible families N = 160
HHC that develop TB
pairs N = 62
Study population
pairs N = 43
RFLP did not match
pairs N = 13
Genomic sequencing
pairs N = 26
No growth
pairs N = 2
Circulating strain
pair N = 2
Final pairs N = 24 
Insufficient WGS sequencing
coverage
pair N = 1
Phylogenetically unrelated
strains
pair N = 1
Failure to consent
pair N = 1Cultures not found for
secondary cases
pairs N = 18
Fig. 1 Sample inclusion chart. IC index case, HHC household contact.
Table 1 Clinical characteristics of secondary M. tuberculosis
cases from each TB pair according to time of reactivation.
Variablea Early reactivation
(0–2 yrs)
Late reactivation
(>2 yrs)
p valueb
Age (years) 23.4 (n= 11) 29.5 (n= 13) 0.35
Gender 0.41
Male 7 5
Female 4 8
Body mass index 19.9 (n= 6) 21.0 (n= 11) 0.42
BCG vaccine scar 1.0
Yes 10 10
No 1 2
NA 0 1
HIV status (self-
reported):
1.0
HIV Positive 0 0
HIV Negative 6 12
NA 5 2
PPD max (mm) 12.9 (n= 10) 14.7 (n= 8) 0.56
Alcohol use 1.0
Yes 1 1
No 4 5
NA 6 8
Smoking 1.0
Yes 1 1
No 4 5
NA 6 8
Comorbiditiesc 0.47
Yes 0 2
No 5 5
NA 6 7
aMeans are shown for numerical variables (age, body mass index, and PPD max), frequencies
are shown for categorical variables (gender, BCG vaccine scar, HIV status, alcohol use, smoking,
and co-morbidities). Not all data was available for each patient. Each variable value is indicated
by the sample size used to derive the value.
bp Values comparing clinical characteristics in early vs. late reactivation are estimated using
exact tests for categorical values (using available data only) and Wilcoxon rank sum tests for
numerical variables.
cComorbidities include: renal failure, diabetes, cancer, rheumatoid arthritis, COPD or gastric surgery.
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difference of 13. This result was maintained with an alternate
SNP detection pipeline (Supplementary Table 3 and Supple-
mentary Fig. 5). To test whether our results were influenced by
HHCs who might possibly have acquired TB by exogenous re-
infection from another TB patient in the community rather than
the IC, we performed a subgroup analysis limited only to the 14
TB pairs that had a unique RFLP pattern not shared with any
other isolate in the community (highlighted rows in Supple-
mentary Table 2). This analysis showed similar findings to the full
cohort (p= 0.78, Supplementary Fig. 6). To test whether the
presence of sub-populations developing over time could influence
the results, we studied the percent read support for each SNP
across the genomes of our TB pairs over time. As shown in
representative histograms (Supplementary Fig. 7), TB pairs that
were diagnosed with TB even 63 months apart did not differ in
intra-patient SNP diversity, which was very low in all samples.
Mutation rate versus generation time. The use of SNP differ-
ences as a replication clock assumes a fixed relationship between
generation times and mutagenesis throughout the latency-disease
spectrum. However, it is difficult to verify each of these measures
during latency in humans due to a lack of active infection in LTBI
that can produce culture positive sputum samples. Assuming a
fixed 18 h generation time during latency, equal to that reported
for log phase growth in M. tuberculosis cultures25, we estimated
the mutation rates (mutations/bp/generation) using a Poisson
model for the number of mutations assuming a fixed common
generation time for all TB pairs and used bp×generations as the
denominator (by using its log as an offset in the model). We
similarly fit a Poisson model to the SNP differences using the
observed latency period as a continuous variable using the same
offset, which showed a significant decrease in mutation rate with
longer latency (two-sided p < 0.001, Fig. 3b, see Supplementary
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Fig. 3 Mutation accumulation and mutation rate versus generation time during latency. a Scatter plot showing the number of SNPs that differed between
the n= 24 IC and the HHC isolate pairs (y-axis) as a function of the duration ofM. tuberculosis latency (x-axis). The curve through the points was estimated
using a loess local regression with a second degree polynomial and symmetric re-descending M estimator with Tukey’s biweight function. b Mutation rate
as a function of latency duration (months between IC and HHC TB diagnosis). The generation time is held constant at 18 h as seen in actively replicating
M. tuberculosis in vitro. The smooth line shows the Poisson regression fit to the number of SNPs using t, the observed latency period in months, as the
independent variable for each participant using an offset N×(t/g), where N is 0.973×genome size and t/g is the number of generations and g is set to 18 h.
The coefficient for t was estimated to be −0.053 (95% confidence interval: −0.078, −0.029) and was significantly different from 0.0 (two-sided p <
0.001). The point where the month between IC and HHC TB diagnoses was 0 was set to 1 month when fitting the model in order for it to contribute to the
Poisson model and as is displayed as at month 0 as ^. Source data are provided as a Source Data file.
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Table 2 for raw data). Since the number of generations that
elapsed during latency is inversely proportional to the generation
time, the lack of SNP accumulation as a function of time in
latency can be explained either by a decrease in bacterial mutation
rate or a decline in bacterial replication leading to increased
generation times during LTBI, or a combination of both. We
therefore performed an analysis where both mutation rates
(number of mutations per generation) and generation times could
vary, calculating the mutation rate over a range of generation
times20 (18–318 h) (Fig. 4). When we binned the data into [0–2]
and (2–6] years latency periods, we found that the mutation rates
are substantially lower for the second period, estimated at 8.36 ×
10−10 [95% confidence interval (CI): 3.71 × 10−10, 1.88 × 10−9]
mutations per (bp×generation) in ≤2 years of latency, to 3.81 ×
10−10 [95% CI: 1.70 × 10−10, 8.53 × 10−10] >2–6 year-long LTBI;
however, the difference is not significant, two-sided p= 0.18. An
analysis where we binned the data into three latency periods of
[0–2], (2–4], and (4–6] years showed a statistically significant
decline in the mutation rate over time (Supplementary Fig. 8).
To further understand how quickly bacteria enter a quiescent
state post exposure, we simulated new SNP incidence during
LTBI and found that majority of SNPs appear in a brief time
window (assuming the bacterial generation time during LTBI to
be similar to that during active TB). Thus, it is likely that majority
of SNPs appear before the bacteria enters a quiescent state (i.e.,
soon after infection) or after the bacteria exits the quiescent state
leading to reactivation of active TB (see Supplementary Methods).
Oxidative stress during latency. It has been suggested that the
intracellular environment likely occupied by latent M. tubercu-
losis exposes the bacteria to excessive oxidative stress compared to
active TB20. In particular, mutations due to cytosine deamination
(cytosine to thymine and guanine to adenine) and 8-oxoguanine
(guanine to thymine and cytosine to adenine) were reported to be
abundant in macaques that reactivated to TB within 1–2 years
post infection20. We analyzed the proportion of oxidative stress
mutations in all TB pairs compared to other types of mutations.
Our results indicate that the proportion of oxidative stress
mutations within the first 2 years of latency was indistinguishable
(two-sided chi-square test p-value= 0.36) from that where the
HHC developed disease 2–6 years after exposure to the IC
(Fig. 5). This suggests that mutations attributed to oxidative
stress, or similar mutations that could be the result of alterations
in bacterial metabolism are not preferentially accumulating in M.
tuberculosis during latency in humans.
Detailed analysis of SNPs generated between TB pairs. We
performed an analysis of the SNPs that developed between all TB
pairs to identify any patterns peculiar to our data set where all
periods of latency where well defined. This analysis (Supple-
mentary Table 2) revealed that 47.2% of SNPs were non-synon-
ymous, 30.2% were synonymous and the remaining 22.6% SNPs
were found in M. tuberculosis intergenic regions (Supplementary
Fig. 9). All SNPs were found in different genes, suggesting that
these SNPs likely did not have a functional role in latent infection
(Supplementary Tables 4 and 5), although it is difficult to draw
definitive conclusions about mutational distributions given the
small numbers of mutations observed.
Discussion
Our results suggest that mutation rates are relatively high (and/or
generation times are relatively low) up to 2 years after M.
tuberculosis infection, which might more properly be considered
an early incubation period or “early latency”. M. tuberculosis then
transitions into a physiological state of low mutation rate (or
longer generation time) for the remaining duration of the latency
period, which might be termed “late latency”. Our results shed
light on the long observed phenomenon that most cases of sec-
ondary TB occur within the first one to two years after infection5,
with the highest rate of reactivation occurring within the first
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Fig. 4 Changes in mutation rate during latency with varying generation time. Mutation rate (mutations per (bp×generation)) is shown for generation
times ranging from 18 to 320 h for IC–HHC pairs grouped by the number of years between IC diagnosis and reactivation of tuberculosis in the HHC. The
dark blue line is obtained from the regressions and shows the estimated mutation rate for a given generation time (x-axis) and light blue regions show 95%
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8.36 × 10−10 mutations per (bp×generation) as seen in early latency (years 0–2, inclusive) with generation times held constant at 18 h. Source data are
provided as a Source Data file.
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year. This high-risk period approximates the period that we have
termed early latency. On the other hand, TB reactivation rates
from LTBI drop dramatically after the first two years of
M. tuberculosis infection. This relatively protected period corre-
sponds to the period that we have termed late latency. Our results
also suggest that the optimal treatment for LTBI may vary
depending on the time since infection is established, because
many anti-tubercular drugs are only effective against actively
replicating bacteria.
It is not possible to directly measure M. tuberculosis generation
times in human latent infection. Instead, we performed an ana-
lysis that examined mutation rates over a wide range of possible
generation times. We suggest however, with some assumptions,
that it may be possible to use mutation rates to directly infer
generation times during latent TB infection because we did not
find any evidence that the distribution of mutations attributable
to oxidative damage in early latency was significantly different
from that in late latency. The use of mutation rates defined under
laboratory conditions combined with measures of mutation
accumulation over time in nature has been used to estimate
replication rates in a wide variety of bacteria16. Assuming an 18 h
generation time during latency, equal to that reported for log
phase growth in M. tuberculosis cultures25, our results predicted
that mutation rates decreased with longer latency. Our binned
analysis, which is known to result in reduced efficiency26, com-
paring 0–2 years vs. >2 years LTBI suggested no difference in
mutation rates. On the other hand, using mutation rate as a
replication clock would lead to the conclusion that most of
latency is characterized by a virtual absence of M. tuberculosis
replication.
Our results may help to resolve the apparently contradictory
conclusions reached by Ford et al.20 and Colangeli et al.21 by
suggesting that both studies are likely correct. Ford et al. found
that bacterial mutation rates per generation and generation times
in cynomolgus macaques latently infected for <2 years were
similar to that observed in active disease. In contrast, Colangeli
et al. found that two human cases of latency lasting up to 20 years
showed long bacterial generation times, especially after adjusting
for the mutations measured in the two TB cases that developed
within 2 years after exposure. The contradiction between these
two studies is resolved when it is appreciated that Ford et al. were
likely studying early latency and Colangeli et al. were likely
studying late latency.
One limitation of all HHC studies tracking TB transmission is
the lack of absolute certainty that the index case was the source of
bacteria that infected the HHC. We were fortunate in that TB
transmission is relatively low in our Brazilian study community.
Bayesian modeling of household vs. community TB transmission
in the Vitória Brazil region estimated that only 1/5th of all HHC
in this region are potentially infected from the community instead
of the index patient27. Furthermore, we excluded TB pairs
infected with M. tuberculosis strains that were commonly circu-
lating in Vitória, and a sensitivity analysis including only TB pairs
infected with unique strains produced identical results to the
whole cohort. We could also not exclude the possibility that both
the index and secondary case had been infected by a third source
case. However, this is highly unlikely to have occurred, at least in
the 14 TB pairs for which no other RFLP identical M. tuberculosis
isolate was identified in the study community.
Our study is also limited by the nature of TB transmission and
pathogenesis. TB is transmitted by aerosols, and the infecting
dose is likely to be small, hence transmission bottlenecks may
have caused some of the differences in the observed mutation
rates between TB pairs. Indeed, our study did include one outlier
that appeared to have a much higher mutation rate than any of
the other TB pairs. However, a repeat analysis excluding this pair
did not appreciably change our findings. Furthermore, this study
was only able to detect mutations that were fixed in the
M. tuberculosis population. Additional mutations that were even
slightly deleterious might have been eliminated due to selection,
leading to some underestimation of mutation rates. Thus, our
study is most relevant to the population of fit bacteria that pose a
risk for disease reactivation and not to these potential biological
dead ends. We could not definitely conclude that the mutations
which occur during early latency were not in fact a product of the
post latency period, when all latent infections reactivate into
active TB. However, the work by Ford et al. suggests that most of
these mutations did indeed occur during an early latent period.
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Fig. 5 Oxidative stress during latency. The proportion of mutations (y-axis) is shown for each mutation type (x-axis) for early (reactivation within 2 years,
shaded bars) and late (reactivation after 2 years, black bars) latency. The incidence of mutations due to oxidative stress (cytosine deamination: C>T, G>A;
and 8-oxoguanine: G>T, C>A) are indistinguishable in early and late latency. The number of mutations in early latency (years [0,2]) are: C>T: 4, G>A: 4,
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G>T: 1, C>A: 4, G>C: 7, C>G: 1, T>C: 1, T>A: 1, T>G: 1, A>C: 1, A>T: 2, A>G: 3. Source data are provided as a Source Data file.
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Nor can we be certain that the latency periods calculated for each
TB pair are completely accurate, since the index case may have
been infectious before it was detected as having TB disease in the
household. Thus, it is possible that some of the latency periods in
our study were longer than our estimates. However, neither of
these possibilities would change the central findings of our study.
In either scenario, our results show that mutations do not accu-
mulate as a function of the period of latency lasting >2 years.
Thus, most of latency is characterized by bacterial quiescence.
Our study was performed in individuals with few co-morbidities,
and none were known to have HIV-1 infection. It is possible
that our findings would have been different if we had included
individuals with risk factors that increase rates of TB reactivation.
The high rates of LTBI reactivation known to occur in individuals
with HIV-1 or other immunosuppressive conditions may be
explained by ongoing replication of latently infected bacteria past
the period that would normally define early latency. Finally, all
the TB pairs in our study were infected with M. tuberculosis
lineage 4. Although our study analysis benefits from this
high degree of strain uniformity, it is possible that other TB
lineages may exhibit different mutation rates × generation times
during LTBI.
In summary, our study shows that measuring mutation rates
per year of latency as well as potential bacterial generation times
during LTBI shows that latency includes a prolonged period of
low mutation rates or long generation times, likely indicating a
quiescent state. We also show that mutations due to oxidative
stress or alterations in bacterial metabolism do not confound this
conclusion. Our findings suggest that modifying existing pre-
ventive therapy to accommodate the physiological transition of
M. tuberculosis into a non-replicating state during prolonged
latency is likely to improve the efficacy of LTBI treatment.
Methods
Human participants. The study was approved by the Comitê de Ética em Pesquisa
do Centro de Ciências da Saúde—Universidade Federal do Espírito Santo and the
Comissão Nacional de Ética em Pesquisa under protocol number 14151, and the
Institutional Review Boards of Boston University Medical Center and Rutgers
University—New Jersey Medical School (formerly University of Medicine and
Dentistry of New Jersey). We obtained written informed consent and assent in
Portuguese in accordance with age-specific ethical guidelines of participating
institutions.
Study population and study samples. We obtained M. tuberculosis cultures from
participants enrolled in a HHC study performed at the Núcleo do Doenças
Infecciosas (NDI) located in Vitória, the capital city of the State of Espírito Santo,
Brazil. Participant enrollment and sample collection has been described22. In brief,
the NDI has organized a network of 16 TB clinics in the metropolitan region of
Vitória28, which facilitated the identification of index TB cases as well as secondary
TB cases in HHCs after initial ascertainment. All consecutive HIV-uninfected,
pulmonary TB patients attending NDI clinics with a first episode of TB and a
sputum with ≥2+ AFB smear and ≥3 HHCs who did not meet previously described
exclusion criteria22 were eligible for enrollment as IC. A HHC was defined using
culturally adapted criteria of close contact22. All participating HHCs were enrolled
within the first two weeks after the index TB patient had presented to the clinic.
Co-prevalent active TB disease was excluded in all HHCs eligible for the current
study by a detailed history and sputum examination at the time of the original
HHC investigation. Chest X-rays examination was performed in all participants
with symptoms suggestive of TB. To identify secondary cases of TB in the HHCs
up to 6 years after identification of the index case, HHC study participants were
matched with an extensive clinical and microbiological database “TB notes” of TB
cases and M. tuberculosis cultures isolated in the greater Vitória region. This search
identified 72 cases of TB in the HHCs. Seven of the HHC were found to have had a
case of TB that predated the onset of TB in the “index case” that had led to the
HHC investigation. In these seven cases, the first occurring TB case was defined as
the index case and the second occurring TB case was re-defined as the secondary
TB case.
Culture of M. tuberculosis isolates and DNA isolation. M. tuberculosis clinical
isolates were cultured on Lowenstein Jensen (LJ) slants. M. tuberculosis H37Rv was
grown from the same stock culture multiple times in Middlebrook 7H9 (BD,
Sparks, MD) with 10% OADC supplement (BD, Sparks, MD) and 0.05% (w/v)
Tween-80 (Sigma, St. Louis, MO). Each strain was plated on Middlebrook 7H10
agar (BD DifcoTM) containing 0.02% glycerol and 10% OADC (BD DifcoTM
BBLTM) and incubated at 37 °C. After substantial growth was observed, three loops
of culture were scraped and suspended in SET (25% sucrose, 50 mM EDTA,
50 mM Tris pH 8.0) buffer containing 100 mg/mL lysozyme. DNA was then
extracted using phenol–chloroform followed by purification using qiagen columns
(Qiagen)29. DNA was further purified using QIAamp DNA mini kit.
RFLP identification. M. tuberculosis isolates, stored at −70 °C, were sub-cultured
in Ogawa medium and all viable isolates were typed by the IS6110 RFLP according
to a standardized method30. The M. tuberculosis 14323 strain was used to compare
patterns. The band patterns were analyzed with BioNumerics software version 7.6
(Applied Maths, Sint-Martens-Latem, Belgium). A dendrogram was constructed to
elucidate the degree of similarity among the isolates. Unweighted pair group
method with arithmetic mean (UPGMA) and the dice index (1.0% tolerance, 1.5%
optimization) were used. Cluster analysis was performed using a cluster definition
of two or more M. tuberculosis isolates RFLP hybridization patterns that were
identical or that differed by only one band.
Whole genome sequencing. The Illumina libraries for clinical isolates were pre-
pared using Nextera XT Index and Library prep and the DNA samples were
multiplexed and sequenced on two lanes in Illumina HiSeq 2500 by the Genome
Technology Center of the New York University. The Illumina libraries of in vitro
cultures of laboratory strain H37Rv were prepared using the Illumina’s Nextera
Flex Library prep kit and Illumina’s Nextera DNA CD Index kit (for adapters), and
the normalized DNA samples were sequenced on NextSeq 550 Illumina system at
The Genome Center of Rutgers-NJMS, Newark.
SNP identification. SNPs were identified using two SNP detection pipelines that
are specific to M. tuberculosis: MTBseq31 (version 1.0.4) and SNPTB32 (version
1.0.0). In the MTBseq pipeline, raw reads were mapped to the reference genome
(NCBI Accession: NC_000962.3) and SNPs that were supported by at least 75% of
the reads, with a minimum of four reads in both forward and reverse directions
containing the SNP, and with at least four reads having a minimum phred score of
20 were called. SNPs found in the repetitive regions of the genome or in the genes
associated with drug resistance were excluded. SNPs within a window of 12 bases
were excluded as well. In the SNPTB pipeline, the raw reads were filtered using
Trimmomatic33 (version 0.36) and then aligned to the reference genome (NCBI
Accession AL123456.3) using Bowtie 234 (version 2.2.6). Since each sample was
sequenced twice on two separate Illumina lanes, the mapped reads were merged for
each sample using SAMtools35 (version 1.2) and high-confidence SNPs (QUAL
score > 200) were identified using SAMtools (version 1.2)35 and BCFtools36 (ver-
sion 1.2). All SNPs had a minimum coverage of 20 in all samples. SNPs found in
the highly repetitive PE/PPE gene family were ignored.
SNP validation. The SNPTB pipeline was tested on four cultures of the laboratory
reference strain of M. tuberculosis, H37Rv. Each culture was grown separately from
the same stock and sequenced on the Illumina NextSeq platform following either 0,
1, 2, or 3 passages. The pipeline found the four cultures to be genetically identical
(ignoring indels, and SNPs/indels in the PE/PPE genes). This ruled out laboratory
culture, DNA extraction, or sequencing procedures as a source of SNPs.
SNP annotation. The SNPs were annotated as synonymous or non-synonymous
by inserting the nucleotide change in the reference gene sequence and comparing
the translations of the mutated and the reference gene sequences. SNPs were
designated as intergenic if they lied in non-genic regions of the H37Rv genome.
The SNPTB bioinformatics pipeline for identifying and annotating SNPs in
M. tuberculosis (synonymous, non-synonymous, or intergenic) is available at
https://github.com/aditi9783/SNPTB32.
Phylogenetic analysis. A distance matrix was constructed by determining the
pairwise SNP differences between all samples (24 IC and 24 HHC= 48 total
samples). This distance matrix was then used to construct an unrooted phyloge-
netic tree using the neighbor-joining method as implemented in the PHYLIP
package (version 3.696)37,38. The tree was drawn using the drawtree program of the
PHYLIP package.
Detecting mixed infections. Sobkowiak et al. suggests that M. tuberculosis sam-
ples with >10 heterozygous sites are candidates for potential mixed infections39.
We analyzed mapped reads for our 48 samples for presence of multiple poly-
morphisms at genomic positions with coverage >20 such that each SNP had at least
5% read support. None of the samples in our study had >10 heterozygous sites.
Lineage detection. The VCF files containing SNPs for each of the samples were
submitted to the SNP-IT program to detect M. tuberculosis lineages for the
samples40.
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Mutation rate calculation. The mutation rate per bp×generation was calculated as
follows20. Briefly, the mutation rate per bp×generation is defined as
μ ¼
Pn
i¼1 mi
N Pni¼1 ti=gð Þ
ð1Þ
where μ is the mutation rate, mi is the number of SNPs that differ in the ith
IC–HHC pair out of n pairs, N is the genome size (since we had, on average, reads
covering 97.3% of the M. tuberculosis genome, N= 0.973 × L where L is reference
genome size), ti is time since infection (in hours), and g is generation time (in
hours). Since ti was captured in months, when estimating the mutation rate per
bp×generation the single HHC diagnosed with TB in the same month as the index
TB case had the infection time set to 1 month and then converted to hours.
Statistics. Patient characteristics between HHC that reactivated TB early were
compared to HHC that reactivated TB late using Wilcoxon rank sum test (for
numerical values) and Fishers exact test (for categorical values) as implemented in
the SciPy package (version 1.0.0)41. Two-sided p-values of these tests are reported
in Table 1. The variation of mutation rate over a range of generation times was
analyzed using a Poisson regression (as implemented in R using the glm function)
and robust variances (using the sandwich package) to control for deviations from
distributional assumptions. Poisson models were used to obtain mutation rates per
(bp×generation) by using bp×generation an offset. A Poisson model was fit for
each latency time period, 0–2 years and >2–6 years, with n= 9 and 13 IC–HHC
pairs, respectively, using an intercept only model. By combining data from all pairs
and fitting a model using a binary variable that indicated membership in the two
latency time periods as the independent variable, we tested whether stress muta-
tions were more abundant in late latency (reactivation after >2 years of latency).
We also fit a Poisson model using the latency period as a continuous independent
variable and tested whether the parameter was significantly different from 0.0.
Testing of Poisson model parameters used a two-sided chi-square test using the
robust variance.
Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.
Data availability
Genomic data (raw sequence reads) from clinical isolates are available from NCBI
Sequence Read Archive via BioProject accession number PRJNA475130. H37Rv
(laboratory strain) genomic data is available from NCBI Sequence Read Archive via
BioProject ID accession number PRJNA607763. The MTBseq pipeline used M.
tuberculosis H37Rv reference genome at NCBI, Accession: NC_000962.3, for SNP
detection. The SNPTB pipeline used M. tuberculosis H37Rv reference genome at NCBI,
Accession: AL123456.3, for SNP detection. Source data are provided with this paper.
Code availability
The bioinformatics pipeline MTBseq is available at https://github.com/ngs-fzb/
MTBseq_source. The bioinformatics pipeline SNPTB is available at https://github.com/
aditi9783/SNPTB. All other scripts for data analyses are available at https://github.com/
aditi9783/TB_latency_scripts. All scripts are publicly available for use under the MIT
license. Questions regarding python code usage should be addressed to the author A.G.,
and questions regarding R code usage should be addressed to author S.K.
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